Key facts
as of Sep 2026- ImmunoMet’s last known valuation is $46.0M (Apr 2025).
- It has raised $43.8M; the latest was Later Stage VC ($840K) in Feb 2026.
- Notable investors include Johnson & Johnson Innovation - JLABS, InterVest, G.N. Tech Venture Capital, Hanall Biopharma, Incon Company — 9 tracked in total.
- 3 institutional filers report fund marks on ImmunoMet across 12 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ImmunoMet
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in ImmunoMet shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
3 filers · latest Jun 20263 SEC-registered funds reported 12 fair-value marks on ImmunoMet between May 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for ImmunoMet are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmunoMet
Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies include drugs and metabolic regulators to increase patient survival by disrupting cancer metabolism and enhancing immunity by targeting the cellular metabolism of drug-resistant cancer subpopulations and immunosuppressors of anti-cancer effector T cells, enabling healthcare providers to provide long-term survival and quality of life for patients.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2015
- Employees
- 7
- Website
- immunomet.com/
- Ownership
- Privately Held (backing)